Table 1.
Demographics and clinical characteristics of participants.
| Characteristics | CI (n = 17) | CN (n = 17) | HC (n = 20) |
|---|---|---|---|
| Age (years) | 54.18 ± 13.97 | 49.53 ± 12.17 | 32.05 ± 4.62 |
| Gender | F = 5, M = 12 | F = 6, M = 11 | F = 7, M = 13 |
| Education (years) | 10.00 ± 3.72 | 11.41 ± 3.12 | 16.2 ± 3.75 |
| BMI (kg/m2) | 24.85 ± 3.76 | 23.53 ± 3.14 | 23.15 ± 3.17 |
| PANSS | 55.18 ± 10.51 | 56.59 ± 13.00 | N/A |
| Smoker (n, %) | 5 (29.4%) | 4 (23.5%) | 3 (15%) |
| MoCA | 16.88 ± 4.47 | 27.59 ± 1.23 | 27.95 ± 1.23 |
| Types of antipsychotic drugs | |||
| Quetiapine (n, %) | 1 (5.9%) | 3 (17.6%) | N/A |
| Olanzapine (n, %) | 8 (47.1%) | 7 (41.2%) | N/A |
| Risperidone (n, %) | 1 (5.9%) | 3 (17.6%) | N/A |
| Aripiprazole (n, %) | 6 (35.3%) | 9 (52.9%) | N/A |
| Clozapine (n, %) | 7 (41.2%) | 0 | N/A |
| Amisulpride (n, %) | 1 (5.9%) | 0 | N/A |
CI, SCZ patients with cognitive impairment; CN, SCZ patients with cognitive normal; HC, health control. BMI, body mass index; PANSS, the total score of Positive and Negative Syndrome Scale; MoCA, the total score of Montreal Cognitive Assessment Scale. No PANSS score and drug are used in the healthy control group (N/A). Values are expressed as mean ± standard deviation.